The FDA has approved insulin aspart injection (Fiasp, Novo Nordisk), 100 U/mL, as a new mealtime option for children with diabetes—the first fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Diabetes is one of the most common chronic conditions of childhood, with nearly 18,000 new cases…